Milestone Pharmaceuticals FY Conference Summary Company Overview - **Company**: Milestone Pharmaceuticals - **Product**: CARDAMYST (etripamil), a novel calcium channel blocker approved for the treatment of paroxysmal supraventricular tachycardia (PSVT) [3][4] - **Launch Timeline**: Product launched in pharmacies in January 2026, with a commercial launch in February 2026 [4] Industry Context - **Target Disease**: Paroxysmal supraventricular tachycardia (PSVT), characterized by rapid heart rates exceeding 200 beats per minute, affecting over 2 million patients in the U.S. [9][10] - **Market Opportunity**: Approximately 200,000-300,000 new diagnoses annually, with significant costs associated with emergency department visits and hospital admissions [9][10] - **Current Treatment Landscape**: Limited options available for acute episodes, with no new treatments introduced in over 30 years [8][9] Product Details - **Formulation**: Portable nasal spray with two doses for acute episodes [3] - **Onset of Action**: Rapid onset with a peak concentration (Cmax) in 7 minutes [11] - **Shelf Life**: 36 months, with a minimum of 18 months in the launch year [12] - **Patent Protection**: Composition of matter and formulation patents extend through 2042 [12] Commercial Strategy - **Sales Force**: 60 representatives targeting approximately 10,000 healthcare providers (HCPs) [17] - **Market Focus**: Engaging cardiologists and primary care physicians who treat patients seeking help for PSVT [11][17] - **Pricing Strategy**: Wholesale acquisition cost (WAC) set at $1,649, with plans for tiered coverage to ensure affordability for patients [19][20] - **Patient Activation**: Strategies to engage patients dissatisfied with current treatment options to drive them back into the healthcare system [42][43] Financial Overview - **Cash Position**: Reasonable cash balance as of September 2025, bolstered by a recent $75 million royalty payment [5] - **Market Cap**: Approximately $101.6 million, including common shares and pre-funded warrants [30] Pipeline and Future Indications - **Next Indication**: Atrial fibrillation (AFib) with plans for a Phase III study targeting rapid ventricular rates [26][29] - **Market Size for AFib**: Estimated to be 3-4 times larger than the PSVT market, with significant hospital visits associated with acute episodes [26][27] Launch Metrics and Expectations - **Initial Launch Performance**: Early signs of prescription volume growth, with ongoing monitoring of script fill rates and physician engagement [34][38] - **Payer Engagement**: Active discussions with commercial payers, aiming for coverage within 12-18 months [36][37] - **Key Performance Indicators**: Focus on generating scripts, physician awareness, and patient coverage metrics [21][22] Challenges and Considerations - **Physician Hesitancy**: Initial pushback due to lack of awareness and the conservative nature of cardiologists [45][48] - **Patient Journey**: Many patients experience a lengthy and challenging path to diagnosis and treatment, often leading to dissatisfaction with existing options [50][51] Conclusion Milestone Pharmaceuticals is positioned to capitalize on a significant market opportunity with CARDAMYST, addressing a long-standing gap in the treatment of PSVT. The company's strategic focus on physician engagement, patient activation, and a robust pipeline for future indications like AFib suggests a promising outlook for growth and market penetration.

百济神州2月26日公布2025年第四季度及全年财务业绩，跨越盈亏平衡点，告别了长达数年的"烧钱"时代。 全年总收入达53.43亿美元，同比增长40%；第四季度总收入15亿美元，同比增长33%。 展望2026年，公司给出62亿至64亿美元的总收入指引，同比增幅约20%，预期GAAP经营利润7亿至8亿美元。索托克拉等后期血液肿瘤管线产品临近商业 化，将为公司注入下一阶段增长动能。 核心产品：百悦泽称霸赛道，百泽安稳健拓展 百悦泽依托广泛监管批准和深厚临床数据壁垒，在BTK抑制剂市场建立绝对主导地位。ASH年会公布的SEQUOIA试验六年随访及ALPINE长期随访数据，进 一步验证其在初治及复发难治CLL/SLL患者中的持续获益，领先优势持续巩固。 2025年全年GAAP净利润2.87亿美元，一举扭转2024年净亏损6.45亿美元的局面，实现历史性盈利。 | | | 第四季度 | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 2025年 | | 2024年 | 愛動(%) | | 2025年 | | 產品收入 | S 1,476,442 | S | ...

Core Viewpoint - Baoyi Pharmaceutical (02659) has seen its stock price increase by over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential growth in its product pipeline [1] Group 1: Company Overview - Baoyi Pharmaceutical has developed China's first recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the world's first IgG degrading enzyme KJ103, which shows "best-in-class" potential for low pre-storage antibodies and dosing frequency, targeting autoimmune diseases [1] - The company also has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration and is aimed at assisted reproduction [1] Group 2: Commercialization and Revenue Potential - Baoyi Pharmaceutical is transitioning from a pure research phase to commercialization, with its three core products already in various stages of commercialization, new drug application registration, or late-stage clinical trials [1] - According to a report from Xiniu Securities, Baoyi has established a clear commercialization model and timeline, with expectations that products will start contributing significantly to revenue by 2026, particularly KJ017 and SJ02 [1] - The KJ103 product, used for kidney transplant desensitization, is anticipated to start generating revenue from 2027, while other applications for KJ103 will contribute at later stages [1]

Core Viewpoint - On December 31, the company announced a deep global collaboration with AbbVie regarding ZG006, with an upfront payment of $100 million and a total deal value of $1.235 billion. The initial clinical data presented at the ESMO Asia conference showed excellent clinical response rates and good durability in SCLC indications, indicating that this collaboration may accelerate ZG006's advancement in overseas oncology indications and maximize the value of the product pipeline, suggesting a promising future for the company [1][3]. Group 1: Collaboration Details - The company has entered into a global strategic collaboration and licensing option agreement with AbbVie for the development and commercialization rights of ZG006, receiving an upfront payment of $100 million, with potential milestone payments based on clinical progress and licensing options totaling up to $60 million. If AbbVie exercises the licensing option, the company could receive up to $1.075 billion in milestone payments [2][3]. Group 2: Clinical Data and Product Pipeline - ZG006 has shown promising early clinical data in small cell lung cancer (SCLC) at the ESMO Asia conference, with overall response rates (ORR) of 60.0% and 66.7% for the 10 mg Q2W and 30 mg Q2W groups, respectively. The confirmed response rates were 53.3% and 56.7%, with disease control rates (DCR) of 73.3% for both groups. The median progression-free survival (mPFS) was 7.03 months and 5.59 months, while the median duration of response (mDoR) rates at 6 months were 71.8% and 69.5% [4]. Group 3: Commercialization Progress - The company has made breakthroughs in commercialization, with the JAK inhibitor, Jika Xini, expected to be approved by the National Medical Products Administration in May 2025, becoming the first domestically approved JAK inhibitor for treating high-risk myelofibrosis. The product has shown rapid sales growth since its launch in June and has been included in the CSCO guidelines [5]. - The recombinant human thrombin injection is set to launch in 2024, with significant efficacy demonstrated in clinical trials, and is expected to become a core growth driver for revenue [5]. Group 4: Future Catalysts - The company has a clear timeline for key catalysts in 2026, including the continued rollout of insurance policies for the recombinant thrombin and Jika Xini, which are expected to drive sales growth. Additionally, further clinical data for ZG005 and ZG006 is anticipated, along with the ongoing collaboration with AbbVie to advance overseas clinical trials [8]. Group 5: Financial Projections - The company’s revenue projections for 2025-2027 are estimated at 712 million, 1.54 billion, and 2.5 billion yuan, with net profits of -127 million, -77 million, and 147 million yuan, respectively, maintaining a "buy" rating [9].

Core Viewpoint - He Mei Pharmaceutical has submitted a prospectus to the Hong Kong Stock Exchange after the approval of its first new drug, Mufemilast, but faces significant challenges due to weak clinical data compared to competitors and limited market potential [1][2][11]. Company Overview - He Mei Pharmaceutical, established in 2002, focuses on discovering and developing small molecule drugs for autoimmune diseases and tumors [1][11]. - The company has completed several rounds of financing, with a post-investment valuation of 3.9 billion yuan after the E round [1][11]. Financial Performance - The company has not yet commercialized any products and has consistently reported losses, with projected losses of 156 million yuan, 123 million yuan, and 73 million yuan for 2023, 2024, and the first half of 2025, respectively [2][11]. - Cash reserves as of June 30, 2025, are approximately 73 million yuan, which may not sustain operations for a year based on historical cash usage [2][11]. Product Pipeline - He Mei Pharmaceutical has developed seven small molecule candidates, including Mufemilast, which has been approved for treating moderate to severe plaque psoriasis [2][11]. - Mufemilast's clinical efficacy data is significantly lower than that of comparable competitors, with PASI-75 and PASI-90 scores of 53.6% and 32.5% at week 16, respectively [4][14]. Competitive Landscape - The psoriasis treatment market is highly competitive, with 18 approved targeted drugs, including 13 biologics, and several others in clinical development [4][13]. - Mufemilast faces competition from established products with better clinical data and lower prices, which may limit its market entry and profitability [15][11]. Market Challenges - The pricing of psoriasis drugs has been significantly reduced due to national health insurance negotiations, putting pressure on Mufemilast's pricing and profit margins [15][11]. - The market for He Mei Pharmaceutical's unique indication for Mufemilast, treating Behçet's disease, is limited due to the low prevalence of the disease [10][18]. Additional Product Insights - Hemay022, another candidate for treating advanced breast cancer, is in phase III trials but targets a small patient population, which may limit its commercial potential [7][16]. - Clinical data for Hemay022 shows an objective response rate of 29.1% and a median progression-free survival (mPFS) of 9.0 months, which is lower than competitors [9][18].

Core Viewpoint - Haitong International has raised its revenue forecasts for BeiGene (06160) for FY25-27 to $5.3 billion, $6.4 billion, and $7.1 billion respectively, reflecting a three-year revenue CAGR of 23% due to stronger-than-expected market performance of Zebrutinib in the US and Europe [1] Group 1: Financial Performance - In Q3 2025, BeiGene achieved revenue of $1.41 billion, representing a year-on-year increase of 41% and a quarter-on-quarter increase of 7.7%, with product revenue at $1.40 billion [1] - The company reported a gross margin of 86.1%, an increase of 3.1 percentage points year-on-year [1] - R&D expenses were $520 million, reflecting a year-on-year increase of 5.5% [1] Group 2: Product Performance - Zebrutinib's global revenue is expected to approach $3.9 billion in 2025, with Q3 2025 global revenue at $1.04 billion, a year-on-year increase of 50.8% and a quarter-on-quarter increase of 9.6% [1] - In the US, Zebrutinib generated $740 million, a year-on-year increase of 46.7% and a quarter-on-quarter increase of 8.0% [1] - In Europe, Zebrutinib's revenue was $160 million, a year-on-year increase of 67.5% [1] Group 3: Pipeline Developments - In the hematological malignancies area, the focus is on BCL-2 inhibitors and BTK CDAC [1] - Management anticipates data for Sotigalimab (BCL-2 inhibitor) in R/R MCL to be released at the 2025 ASH meeting, with plans to submit a US marketing application for R/R MCL [1] - For BTK CDAC, phase II clinical data for R/R CLL is expected in 1H26, and a phase III trial has been initiated [1] Group 4: Solid Tumor Developments - The company is focusing on CDK4 inhibitors, with ongoing phase II clinical trials exploring two dosage levels, showing high response rates that support the initiation of phase III trials [2] - The B7-H4 ADC (BG-C9074) has completed dose escalation and is currently undergoing dose optimization studies in ovarian cancer, endometrial cancer, and breast cancer [2] - The PRMT5i (BGB-58067) has shown good safety and efficacy data, while the GPC3-targeting T-cell activator has demonstrated effectiveness in previously treated liver cancer patients [2]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were $27.5 million, consisting of $25.7 million from Gemyto and $1.8 million from Zesturi, with Gemyto sales showing a 13% year-over-year growth when excluding CreateX sales from the previous year [22][24] - Net loss for Q3 2025 was $33.3 million, or $0.69 per share, compared to a net loss of $23.7 million, or $0.51 per share in Q3 2024 [24] - Cash, cash equivalents, and marketable securities totaled $127.4 million as of September 30, 2025 [24] Business Line Data and Key Metrics Changes - Gemyto generated net product revenue of $25.7 million, reflecting a 13% increase in underlying demand revenue over the same period in 2024 [6][22] - Zesturi sales were $1.8 million in Q3 2025, with a preliminary demand revenue estimate of $4.5 million for October, indicating strong early momentum [15][22] Market Data and Key Metrics Changes - Zesturi addresses an estimated $5 billion annual market, with expectations to become a standard of care and deliver over $1 billion in peak revenue [5][6] - The company has secured broad coverage across major payers, with Zesturi now accessible to over 95% of covered lives, approximately 296 million eligible patients [16] Company Strategy and Development Direction - The company is focused on the ongoing commercialization of Zesturi and Gemyto, with Zesturi being the primary growth driver [3][4] - A permanent product-specific J code for Zesturi is expected to take effect on January 1, 2026, which is anticipated to accelerate adoption [19][20] - The company plans to submit a New Drug Application (NDA) for UGN-103 in the second half of 2026, with potential approval anticipated in 2027 [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential for Zesturi, citing positive physician feedback and increasing patient enrollment forms [4][5] - The company acknowledged logistical and operational challenges affecting the conversion of patient enrollment forms to actual patient dosing but expects improvements as practices gain experience [18][32] - Management emphasized the importance of the upcoming permanent J code in simplifying reimbursement and reducing barriers to adoption [19][20] Other Important Information - R&D expenses for Q3 2025 were $14 million, primarily driven by costs associated with the phase 3 Utopia trial for UGN-103 [22] - Selling, general, and administrative expenses increased to $37.6 million, driven by Zesturi commercial preparation activities and expansion of the sales force [23] Q&A Session Summary Question: Can you explain the timing for revenue recording and remittance? - Management indicated that the average lag time between patient enrollment form submission and patient dosing is currently 45-60 days, with expectations for gradual improvement as practices gain experience [31][33] Question: What visibility is there into physicians waiting for the permanent J code? - Management noted that many physicians are interested in prescribing Zesturi but are waiting for the permanent J code to take effect [36][40] Question: How are patient enrollment forms tracking month over month? - Management reported steady growth in patient enrollment forms, with some weeks showing equal or greater numbers compared to Gemyto [45][48] Question: What is the expected impact of the J code on lag time for patient dosing? - Management anticipates that the lag time will gradually decrease, potentially reaching below 30 days as practices become more familiar with the process [58][61] Question: Will additional capital be needed in 2026? - Management expressed confidence in their current cash position and operational plans, believing they can reach profitability without needing additional capital [70]

（一家於中華人民共和國註冊成立的股份有限公司） 重要提示 重要提示： 閣下如對本招股章程的任何內容有任何疑問，應徵詢獨立專業意見。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 全球發售 獨家保薦人及保薦人兼整體協調人 聯席整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本招股章程的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明 確表示概不就因本招股章程全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本招股章程，連同本招股章程「附錄七－送呈公司註冊處處長及展示文件」所述的文件，已按照香港法例第32章公司（清盤及雜項條文）條例第342C條的規定由 香港公司註冊處處長登記。香港證券及期貨事務監察委員會及香港公司註冊處處長對本招股章程或上述任何其他文件的內容概不負責。 發售價將為11.60港元。香港發售股份申請人於申請時須支付發售價每股香港發售股份11.60港元，連同1.0%經紀佣金、0.0027%證監會交易徵費、0.00015%會 財局交易徵費及0 ...

Company Overview - Esperion Therapeutics is focused on commercializing life-saving medications, specifically NEXLIZET and NEXLETOL [3] - The company is also developing additional life-saving medications, with a recent R&D Day highlighting interesting compounds [3] Financial Performance - Esperion reported significant momentum in its Q2 results, showing double-digit growth across all metrics [3] Industry Engagement - The company had a successful presence at the European Society of Cardiology, which positively influenced its guidelines [3]

Performance Highlights - The company reported cash and cash equivalents of 1.051 billion [4] - Significant progress in core pipeline with the acceptance of NDA for both 0.01% and 0.02% concentrations of Atropine (NVK002) for myopia in children by the National Medical Products Administration [4][21] - The company is the only one in China with two specifications of Atropine under review [19] Product Pipeline - The company has initiated clinical trials for the new drug application (NDA) of Cyclosporine eye gel for dry eye syndrome, which has been accepted by the regulatory authority [5] - The company has received FDA approval for the Phase III clinical trial application for the same product in the U.S. [5] - The company is advancing its product pipeline with several candidates including BRIMOCHOL™ PF for presbyopia and TAB014 for wet age-related macular degeneration (wAMD) [40][36] Market Expansion - The company is expanding its overseas presence and has established partnerships for drug production and supply in various regions including Australia, New Zealand, and Southeast Asia [60] - The company has covered over 1,200 hospitals across 30 provinces in China, including major eye hospitals [57] - The company is leveraging e-commerce platforms such as Tmall and JD for product distribution [58] Research and Development - The company is focusing on innovative drug formulations and delivery methods to improve patient compliance and reduce treatment burden [47][49] - The company has a comprehensive clinical data set supporting its product candidates, enhancing its competitive advantage in the market [22][29] - The company is preparing for IND submissions for several candidates, including PAN-90806 for wAMD and diabetic macular edema [50][46]